Despite the availability of imatinib mesylate, a targeted therapy for treatment of Chronic myeloid leukemia, primary and secondary resistance to therapy remains a challenge. Also, patients progressing to blast crisis phase show little response to imatinib. Previous studies in the lab on generation of proteomic and genomic profile of imatinib sensitive and resistant CML cells have generated data which is being explored to understand disease progression and concommittent resistance to TKIs. To further understand basis of these observed molecular alterations, this project aims at investigating the profile of microRNA and messenger RNA expression of CD34+ cells from healthy volunteers and patients with CML in CP (with and without resistance to imatinib), AP and BC. The data would help us find the possible miRNA:mRNA interaction that would underlie the imatinib resistance.